DETROIT – Wednesday was the first day of a critical meeting involving the CDC’s advisory committee.
The outside panel of experts is reviewing the ongoing safety and effectiveness data for the COVID-19 vaccines and last week’s recommendation that Pfizer’s boosters be authorized for those 65 and older or at high risk from COVID.
The main question that the advisory committee was driving toward was trying to decide which Americans should receive a third dose of the Pfizer vaccine. That decision won’t be made until Thursday. It will depend on any FDA announcement that is made on Wednesday.
During the nearly 6 hour meeting, the CDC’s panel of outside experts discussed and debated data on the available COVID-19 vaccines. A clear case was made that over time the antibody response to the vaccine decreases, especially in the elderly.
Although the immune response fell, coverage of the variants remained good. That data was presented by Dr. Bill Gruber from Pfizer as they made their case for the need to boost their two-dose series.
The panel also reviewed CDC data on a third dose from the safety monitoring systems in place. There was a fair amount of inquiry and discussion of the risk of myocarditis with a third dose. So far, there is no indication that it is more frequent than following the second dose. It is still considered very rare.
COVID-19 Discussion Forum:
Join our dedicated space to discuss the pandemic. You’re invited to share questions, experiences, insights and opinions.